|Day Low/High||66.50 / 68.20|
|52 Wk Low/High||60.32 / 79.61|
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
Gilead Sciences said Monday that it will boost its stake in Belgian listed biotech Galapagos NV by more than $5 billion in a "transformative" deal that could tap new opportunities for the California-based group in fibrosis and arthritis.
Let's see if either of these names provide an entry this week.
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration.
Some investors like to buy and hold, others choose to be hands-on—buying, selling and capitalizing on short-term profits.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Christi L.
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic...
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc.
Gilead Sciences, Inc. (NASDAQ: GILD) and Carna Biosciences Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses from the ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy.
Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta ® (axicabtagene...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company's senior leadership team.
Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 at 11:30 a.
Kite, a Gilead Company (Nasdaq: GILD), today announced that new data from its cell therapy programs will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from May 31 - June 4, 2019.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP ® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.
Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.
Gilead Sciences' adjusted earnings in the first quarter beat analysts' expectations.
Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.